Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
- Annamycin granted Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases- Interim data expected in the second half of 2022HOUSTON, June 21, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the...
Moleculin Announces Inclusion in the Russell 2000® Index
HOUSTON, June 15, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that as part of the...
Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
- Annamycin was designed to potentially become the first ever non-cardiotoxic anthracycline and has been shown in animal models to accumulate in the lungs at more than 30 times the level of doxorubicin (current standard of care)- Patient enrollment on track to begin...
Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update
- Multiple ongoing clinical studies expected to drive key clinical and regulatory milestones throughout next 18 months -- Significantly strengthened financial position extends cash runway through 2023 -HOUSTON, May 12, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX)...
Moleculin Biotech to Present at the Q2 Virtual Investor Summit
Live video webcast with President and CEO, Walter Klemp, on Monday, May 17, 2021 at 12:30 PM ET HOUSTON, May 11, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...
Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma
HOUSTON, April 14, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced today that the U.S. Food and...
Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial
HOUSTON, April 6, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the engagement of IQVIA...
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases
HOUSTON, March 30, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug...
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020
HOUSTON, March 24, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for...
Moleculin to Participate in Four Upcoming Healthcare Conferences
HOUSTON, March 9, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management...